A Phase 1 interventional study of MDMA hydrochloride, non-racemic 75:25 R(-)/S(+) (Laneo 2.0) and Process-Centred MDMA-Assisted Couple Psychotherapy (PACT-MDMA) in Post-Traumatic Stress Disorder, sponsored by Jeremie Richard. Not yet recruiting at 1 site in Canada. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by Jeremie Richard · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 127 studies in Stress Disorders, Post-Traumatic with a site in Canada — 34 open to participants now, 42 under way, 2 of them phase 3. Stress Disorders, Post-Traumatic · Canada.
Among the 127 studies in Stress Disorders, Post-Traumatic with a site in Canada, this one is the 86th largest by planned enrollment of the 113 interventional ones that give a count, is one of 2 that started in 2027, is one of 3 in phase 1, reaches primary completion later than 37 of the 41 other live ones, and was the 126th registered.
2,689 studies on the registry are indexed under Stress Disorders, Post-Traumatic; 606 are open to participants now.
Browse Stress Disorders, Post-Traumatic studies →34 of the 127 studies in Stress Disorders, Post-Traumatic with a site in Canada are open now. Recruiting first, the newest first:
University of Alberta · Sites in Canada
Ages 18–65
COMPASS Pathways · Sites in Canada, United States
Ages 18+
Lawson Research Institute of St. Joseph's · Sites in Canada
Ages 18+
University of British Columbia · Sites in Canada
Ages 19+ · Women only
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's · Sites in Canada
Ages 18–65
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 417 Stress Disorders, Post-Traumatic studies recruiting now, 188 (45%) set no upper age limit and 203 (49%) stop at 75 or younger; 63 take children under 18; 89 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
127 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 22 · Phase 3 8 · Phase 4 2
First in 2007; this study’s year is marked. 2 started in 2027.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20 is below the median of 69 across 2,203 interventional studies indexed under Stress Disorders, Post-Traumatic.
Median enrollment 54 across the 113 interventional studies, 303 across the 14 observational. Of the 65 that completed or were terminated, 6 (9%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 127 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Jeremie Richard as lead sponsor.
Jeremie Richard has 1 study filed under Stress Disorders, Post-Traumatic — fewer than ten, so there is no comparison to draw.
7 of the studies in Stress Disorders, Post-Traumatic with a site in Canada that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07137845Université de SherbrookeVirtual Reality and Cranial Nerve Non-invasive Neuromodulation to Improve Quality of Life for Veterans | 2026-12 |
| NCT07309302Université du Québec a MontréalPsychosocial Factors and Efficacy of Remote Cognitive Remediation for Post-Traumatic Stress Disorder | 2026-12 |
| NCT07146633Centre for Addiction and Mental HealthEfficacy of an EMDR App for PTSD and SUD | 2027-01-30 |
| NCT06044675RemedyMDMA-Assisted CBCT for PTSD vs CBCT RCT | 2027-03-31 |
| NCT06335043London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sPersonalized Pharmacotherapy Using Pharmacogenetics in Veterans | 2027-04-25 |
Add all 7 to your calendar (.ics) → With an account.
Among the 127 studies in Stress Disorders, Post-Traumatic with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is the first step of a research programme on a new treatment for first responders with post-traumatic stress disorder (PTSD): couple therapy in which both partners take MDMA, under medical supervision, in three of fourteen sessions. The treatment is called Process-Centred MDMA-Assisted Couple Psychotherapy, or PACT-MDMA.
Current treatments help many people with PTSD, but many drop out or improve only in part, and few treatments work directly on the relationship, which PTSD strains and which can help recovery. MDMA-assisted therapy has been tested in large trials in the United States, but these studies' designs have been criticised, and the therapy component of the treatment has rarely been specified or measured. No Canadian study has tested MDMA-assisted therapy in first responders, and none has tested it with couples.
This feasibility study at the University of Ottawa will enrol six to ten couples in which one partner is a current or former first responder with PTSD. It asks whether the treatment can be delivered safely, whether couples can be recruited and kept in the study, and whether the sessions and measures work as planned. It does not aim to prove that the treatment works. Two exploratory hypotheses will be examined: that the partner with PTSD will show a reduction in clinician-rated PTSD severity from baseline to the end of treatment that is maintained six months later, and that the other partner will accommodate PTSD symptoms less while both partners report a better relationship over the same period.
A nurse is present and a physician on call during every MDMA session; all sessions are recorded so that the therapy can be checked for fidelity to its written principles; and the research, therapy and medical roles are kept separate. If this phase succeeds, a second phase would compare PACT-MDMA with standard PTSD therapy in about 24 couples in Ottawa and Montreal, and a third would extend the study to several Canadian sites.
Design. Single-site, single-arm, open-label, mixed-methods Phase I feasibility study with repeated measures at baseline (T0), after each of three treatment cycles (T1 to T3) and at 1, 3 and 6 months after the closing session (T4 to T6). Six to ten couples (12 to 20 participants) will be enrolled. The couple is the unit of treatment; both partners receive the full intervention, including MDMA.
Rationale for the design. Randomisation, placebo and blinding are not used: blinding is not practically possible, since therapists and participants recognise the subjective effects of MDMA, and a placebo or sham-therapy control was judged neither practical nor ethically appropriate for an intensive relational and pharmacological intervention at the feasibility stage. Outcomes are read against published results of cognitive-behavioural conjoint therapy, individual trauma-focused therapies and MDMA-assisted therapy trials. The design responds to the concerns raised in the U.S. FDA review of MDMA-assisted therapy (2024): functional unblinding and expectancy are assumed present and measured (treatment credibility and expectancy at baseline, acute subjective drug effects at each MDMA session); research, therapy and medical functions are assigned to three teams with no overlap in personnel; prior MDMA or psychedelic use is an exclusion criterion; therapists deliver a common protocol under supervision and fidelity is rated from recordings; outcomes are assessed by independent assessors; a 6-month follow-up assesses medium-term durability.
Screening and enrolment. Recruitment is through online advertising, professional networks and printed material in clinics specialising in PTSD near the site. Screening has three stages: a coordinator call (study overview, preliminary eligibility); medical screening by the study physician or delegate (medical and psychiatric history, cardiovascular risk, medications and substances); and a psychotherapeutic intake assessment of both partners (individual stability, relational safety, motivation, capacity for conjoint participation). Participants taking contraindicated medications complete a supervised taper under their own physician before eligibility is confirmed. Final medical eligibility rests with the Medical Director. Each couple receives a CAD 50 gift card on completing the post-treatment questionnaires and CAD 100 on completing the 6-month follow-up.
Intervention. PACT-MDMA is a continuous course of conjoint psychotherapy in which three MDMA-assisted cycles are embedded. Both partners attend all 14 sessions: an introductory session; three cycles each comprising a preparatory session, a full-day MDMA session (6 to 8 hours) and two integration sessions; and a closing session. MDMA sessions are about four weeks apart. Each couple is treated by the same two co-therapists throughout. Sessions are in person, except the introductory and closing sessions, which may be held by telehealth. The psychotherapy is trauma-focused, conjoint and process-centred: participant-led, with safety taking precedence over outcome, consent ongoing and revocable, and preparation and integration treated as essential components rather than adjuncts to dosing. All sessions, including MDMA sessions, are audio- and video-recorded as a condition of participation, for supervision, fidelity rating and safety review.
Investigational product and medical oversight. Laneo™ 2.0 MDMA (MDMA hydrochloride, 50 mg oral capsules; PharmAla Biotech) as a dose of 150 mg, three 50 mg capsules, the same for all participants, with one optional supplemental dose of 50 mg (one capsule) 90 minutes after the initial dose, conditional on medical clearance, the Therapy Team's agreement and the agreement of both partners, given to both partners or to neither (maximum 200 mg per session) ; three dosing sessions per participant (maximum cumulative dose 600 mg MDMA HCl). On each MDMA day a Medical Team member conducts a same-day assessment of each partner and the Medical Director authorises dosing. Vital signs are taken before dosing and before discharge; the co-therapy team observes continuously; on-site nursing staff and an on-call study physician are immediately available; an emergency kit is on site. Predefined stopping rules operate at session, participant and study level, including suspension of enrolment and dosing pending review and notification of the REB and Health Canada. Adverse events are classified by the Medical Team for severity, seriousness, expectedness and relatedness and reported to the REB and Health Canada within the Division 5 timelines.
Analysis. Feasibility is summarised as the numbers screened, eligible, enrolled and retained at each assessment point, with reasons for exclusion and withdrawal; protocol adherence as the proportion of scheduled sessions completed and the frequency and nature of protocol variations, deviations and stopping-rule events; safety as the frequency, severity, seriousness and relatedness of adverse events, reported separately for index participants and partners. Quantitative outcome data are analysed with descriptive statistics and within-subject pre-post comparisons; analyses are exploratory and hypothesis-generating. Qualitative interview data are analysed thematically. The study is not powered to detect statistically significant effects and no formal power calculation applies.
Data management. Data are collected in REDCap and held in encrypted, access-controlled University of Ottawa storage. Participants are identified by a couple code and partner suffix; a single cross-reference file linking identities to codes is held by the project coordinator, separately from research data. Research, medical, therapy, drug-accountability and recording records are held in separate stores with role-based access. Essential records are retained for 15 years as required for Division 5 clinical trials. Results are reported in aggregate with small-sample disclosure safeguards.
Governance and regulation. The sponsor is Dr Jeremie Richard, sponsor-investigator, of the School of Psychology, University of Ottawa; the study is conducted at the School of Psychology's Laboratory for Psychedelic Clinical Research. It requires a Clinical Trial Application and No Objection Letter from Health Canada (Food and Drug Regulations, Division 5), an exemption under section 56(1) of the Controlled Drugs and Substances Act, research ethics board approval and institutional sign-off before enrolment. This feasibility study is the first phase of a planned three-phase programme (feasibility, pilot randomised trial, multi-site trial).
Inclusion Criteria (both partners unless stated):
Exclusion Criteria (both partners, since both receive MDMA):
Final medical eligibility rests with the Medical Director, who may exclude on clinical judgement even where formal criteria are met.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Couples in which one partner is a current or former first responder with PTSD. Both partners receive Process-Centred MDMA-Assisted Couple Psychotherapy: 14 conjoint sessions delivered by the same two co-therapists, comprising an introductory session, three treatment cycles (preparatory session, full-day MDMA session, two integration sessions) about four weeks apart, and a closing session. In each MDMA session both partners receive an oral dose of 150 mg MDMA hydrochloride, with one optional 50 mg supplemental dose 90 minutes later, given to both partners or to neither.
Drug: MDMA hydrochloride, non-racemic 75:25 R(-)/S(+) (Laneo 2.0) · Behavioral: Process-Centred MDMA-Assisted Couple Psychotherapy (PACT-MDMA)
Laneo 2.0 MDMA (75% R(-)-MDMA / 25% S(+)-MDMA hydrochloride; PharmAla Biotech Inc.), 50 mg hard oral capsules; a non-racemic composition used clinically in Australia. Oral dose of 150 mg MDMA HCl (three 50 mg capsules) per MDMA session, the same for all participants regardless of body weight or sex, with one optional 50 mg supplemental (booster) dose (one capsule) 90 minutes after the initial dose, conditional on same-day medical clearance, the Therapy Team's agreement and both partners' agreement, and given to both partners or to neither (maximum 200 mg per session). Capsules are ingested intact under the direction and supervision of an authorised Medical Team member. Three MDMA sessions per participant, about four weeks apart (maximum cumulative dose 600 mg MDMA HCl). Both partners of each couple are dosed concurrently.
Also known as: LaNeo MDMA
Conjoint, trauma-focused, process-centred psychotherapy delivered to both partners by a co-therapy team of two therapists who remain constant across all sessions. Fourteen sessions: an introductory session (60 min); three cycles, each with a preparatory session (90 min), an MDMA session (6 to 8 h) and two integration sessions (90 min each, the first within 24 to 48 h of dosing, the second within two weeks); and a closing session (60 min). Introductory and closing sessions may be held by telehealth; all other sessions are in person. Sessions are not organised around a fixed sequence of exercises; content follows what emerges, under written principles rated for fidelity from session recordings.
Recruitment: number of couples screened, eligible and enrolled, and enrolment rate
Numbers of couples screened, found eligible and enrolled, with reasons for exclusion; couples enrolled per month of open recruitment.
Time frame: From the opening of recruitment through the end of enrolment (approximately 183 days after recruitment opens)
Retention: proportion of enrolled couples completing the three treatment cycles and each assessment point
Proportion of enrolled couples who complete all three treatment cycles (closing session, T3) and who complete the assessments at T1 to T6, with reasons for withdrawal.
Time frame: From enrolment to the 6-month follow-up (T6 = day 304), with completion assessed on days 42, 70, 122, 152, 213 and 304
Protocol adherence: proportion of scheduled sessions completed per protocol, and protocol variations, deviations and stopping-rule events
Proportion of the 14 scheduled sessions completed per protocol for each couple; frequency and nature of protocol variations, deviations and applications of the session-, participant- and study-level stopping rules.
Time frame: From the introductory session (day 14) to the closing session (T3 = day 122)
Therapist fidelity to the PACT-MDMA model (PACT-MDMA Fidelity Rating Scale, PACT-FRS)
Adherence, competence and differentiation ratings by independent raters from recordings of all MDMA sessions and a stratified sample of other sessions; therapist self-ratings; inter-rater reliability; drift events across a therapist's consecutive ratings.
Time frame: From the introductory session (day 14) to the closing session (T3 = day 122)
Safety: frequency, severity, seriousness and relatedness of adverse events
Adverse events, serious adverse events, serious adverse reactions and suspected unexpected serious adverse reactions, classified by the Medical Team by severity, seriousness, expectedness and relatedness and including psychological and relational events, reported separately for index participants and partners.
Time frame: From enrolment (T0 = day 0) to the 6-month follow-up (T6 = day 304)
Change in clinician-rated PTSD symptom severity (CAPS-5), index participant
Clinician-Administered PTSD Scale for DSM-5, structured interview assessing DSM-5 PTSD diagnosis and symptom severity across the 20 DSM-5 symptoms, administered by an independent assessor to the partner with PTSD.
Time frame: Baseline (T0 = day 0), post-treatment (T3 = day 122), and 1, 3 and 6 months after the closing session (T4 = day 152; T5 = day 213; T6 = day 304)
Change in self-reported PTSD symptom severity (PCL-5), both partners
PTSD Checklist for DSM-5, 20-item self-report mapping onto the DSM-5 PTSD symptoms. Completed separately by each partner.
Time frame: Baseline (T0 = day 0), after each treatment cycle (T1 = day 42; T2 = day 70; T3 = day 122) and 1, 3 and 6 months after the closing session (T4 = day 152; T5 = day 213; T6 = day 304)
Change in partner accommodation of PTSD symptoms (SORTS), support partner
Significant Others' Responses to Trauma Scale, assessing partner responses and accommodation of PTSD symptoms; completed by the partner without PTSD.
Time frame: Baseline (T0 = day 0), after each treatment cycle (T1 = day 42; T2 = day 70; T3 = day 122) and 1, 3 and 6 months after the closing session (T4 = day 152; T5 = day 213; T6 = day 304)
Change in relationship satisfaction (Couple Satisfaction Index, CSI), both partners
Couple Satisfaction Index, self-report measure of relationship satisfaction.
Time frame: Baseline (T0 = day 0), after each treatment cycle (T1 = day 42; T2 = day 70; T3 = day 122) and 1, 3 and 6 months after the closing session (T4 = day 152; T5 = day 213; T6 = day 304)
Change in relationship quality (Quality of Relationships Inventory, QRI), both partners
Quality of Relationships Inventory: Support, Depth and Conflict subscales.
Time frame: Baseline (T0 = day 0), after each treatment cycle (T1 = day 42; T2 = day 70; T3 = day 122) and 1, 3 and 6 months after the closing session (T4 = day 152; T5 = day 213; T6 = day 304)
Change in attachment anxiety and avoidance (ECR-M16), both partners
Modified Experiences in Close Relationships scale, 16 items.
Time frame: Baseline (T0 = day 0), after each treatment cycle (T1 = day 42; T2 = day 70; T3 = day 122) and 1, 3 and 6 months after the closing session (T4 = day 152; T5 = day 213; T6 = day 304)
Change in depressive symptoms (PHQ-9), both partners
Patient Health Questionnaire-9, 9-item measure of depressive symptom severity.
Time frame: Baseline (T0 = day 0), after each treatment cycle (T1 = day 42; T2 = day 70; T3 = day 122) and 1, 3 and 6 months after the closing session (T4 = day 152; T5 = day 213; T6 = day 304)
Change in anxiety symptoms (GAD-7), both partners
Generalized Anxiety Disorder-7, 7-item measure of generalised anxiety symptom severity.
Time frame: Baseline (T0 = day 0), after each treatment cycle (T1 = day 42; T2 = day 70; T3 = day 122) and 1, 3 and 6 months after the closing session (T4 = day 152; T5 = day 213; T6 = day 304)
Suicidal ideation and behaviour (C-SSRS), both partners
Columbia-Suicide Severity Rating Scale; presence and severity of suicidal ideation and behaviour.
Time frame: Screening (approximately 7 days before baseline), baseline (T0 = day 0), after each treatment cycle (T1 = day 42; T2 = day 70; T3 = day 122) and 1, 3 and 6 months after the closing session (T4 = day 152; T5 = day 213; T6 = day 304)
Change in experiential avoidance (BEAQ), both partners
Brief Experiential Avoidance Questionnaire, 15-item self-report measure of experiential avoidance.
Time frame: Baseline (T0 = day 0), after each treatment cycle (T1 = day 42; T2 = day 70; T3 = day 122) and 1, 3 and 6 months after the closing session (T4 = day 152; T5 = day 213; T6 = day 304)
Change in psychological flexibility (MPFI-24), both partners
Multidimensional Psychological Flexibility Inventory, 24-item short form covering the six flexibility and six inflexibility processes of the Hexaflex model; higher-order flexibility and inflexibility scales.
Time frame: Baseline (T0 = day 0), after each treatment cycle (T1 = day 42; T2 = day 70; T3 = day 122) and 1, 3 and 6 months after the closing session (T4 = day 152; T5 = day 213; T6 = day 304)
Change in posttraumatic growth (PTGI), both partners
Posttraumatic Growth Inventory, 21 items, five domains of perceived positive change after trauma.
Time frame: Baseline (T0 = day 0), after each treatment cycle (T1 = day 42; T2 = day 70; T3 = day 122) and 1, 3 and 6 months after the closing session (T4 = day 152; T5 = day 213; T6 = day 304)
Change in perceived social support (MOS-SSS), both partners
Medical Outcomes Study Social Support Survey, 19-item measure of perceived functional social support.
Time frame: Baseline (T0 = day 0), after each treatment cycle (T1 = day 42; T2 = day 70; T3 = day 122) and 1, 3 and 6 months after the closing session (T4 = day 152; T5 = day 213; T6 = day 304)
Cross-cutting psychiatric symptoms (DSM-5-TR Level 1 Cross-Cutting Symptom Measure, Adult), both partners
23-item self-report screen of transdiagnostic symptom domains.
Time frame: Baseline (T0 = day 0), after each treatment cycle (T1 = day 42; T2 = day 70; T3 = day 122) and 1, 3 and 6 months after the closing session (T4 = day 152; T5 = day 213; T6 = day 304)
Alcohol, cannabis and drug use (AUDIT, CUDIT-R, DUDIT), both partners
Brief self-report screens for hazardous alcohol, cannabis and drug use.
Time frame: Screening (approximately 7 days before baseline), baseline (T0 = day 0), after each treatment cycle (T1 = day 42; T2 = day 70; T3 = day 122) and 1, 3 and 6 months after the closing session (T4 = day 152; T5 = day 213; T6 = day 304)
Working alliance (WAI-SR), both partners
Working Alliance Inventory, Short Revised, client-rated Bond, Tasks and Goals.
Time frame: After each treatment cycle (T1 = day 42; T2 = day 70; T3 = day 122)
Treatment credibility and expectancy (CEQ), both partners
Credibility/Expectancy Questionnaire.
Time frame: Baseline (T0 = day 0)
Trait absorption (Tellegen Absorption Scale), both partners
34-item true-false trait measure.
Time frame: Baseline (T0 = day 0)
Acute subjective drug effects (DEQ), both partners
Drug Effects Questionnaire visual-analogue ratings (feel, like, high, want more).
Time frame: At each of the three MDMA sessions, respectively on days 28, 56 and 84
Session phenomenology (PIQ, EBI, 5D-ASC, MEQ-30), both partners
Psychological Insight Questionnaire; Emotional Breakthrough Inventory (6 items); 5-Dimensional Altered States of Consciousness Rating Scale; Mystical Experience Questionnaire-30 (exploratory for MDMA).
Time frame: At each of the three MDMA sessions, respectively on days 28, 56 and 84
General psychotherapeutic change mechanisms (GCMQ), both partners
General Change Mechanisms Questionnaire, 25 items, five mechanisms.
Time frame: After each treatment cycle (T1, T2, T3), respectively on days 42, 70 and 122
Persisting effects (PEQ-SF), both partners
Persistent Effects Questionnaire Short Form, 14 items plus 3 on spirituality, well-being and meaning.
Time frame: After each treatment cycle (T1 = day 42; T2 = day 70; T3 = day 122) and 1, 3 and 6 months after the closing session (T4 = day 152; T5 = day 213; T6 = day 304); not at baseline
Participant experience (semi-structured qualitative interview), each partner separately
Thematic analysis of interviews following the PACT-MDMA Participant Experience Interview Guide: experience of self, of the relationship, of the MDMA sessions, of the periods between sessions; barriers and facilitators.
Time frame: Baseline (T0 = day 0), after each treatment cycle (T1 = day 42; T2 = day 70; T3 = day 122) and 1, 3 and 6 months after the closing session (T4 = day 152; T5 = day 213; T6 = day 304)
Plan to share: No — Individual participant data will not be shared. The study enrols 12 to 20 participants in couples, so that individual-level data carry a risk of re-identification even after de-identification; results will be reported in aggregate with small-sample disclosure safeguards, as set out in the study's data protocol.
No publications or documents are linked to this record.
Start is estimated for Apr 2027; primary completion for Oct 2028, 18 months later.
Of 47 non-industry phase 1 interventional studies under Stress Disorders, Post-Traumatic, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 59. This study's planned 18 months is below that.
Counting every sponsor, half of 52 studies reached it within 33 months; a quarter within 17 and three quarters within 54.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Stress Disorders, Post-Traumatic →